牛牛AI助理已提取核心訊息
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced on March 4, 2024, the appointment of Dr. Ramiro Ribeiro as its new Chief Medical Officer, effective March 1, 2024. Dr. Ribeiro, a trained retinal specialist, succeeds Dr. Dario Paggiarino, who has served in the role since 2016 and will depart the company on March 31, 2024. Dr. Ribeiro's previous experience includes serving as Vice President, Head of Clinical Development at Apellis Pharmaceuticals, where he led the global Phase 3 clinical program in Geographic Atrophy. EyePoint Pharmaceuticals is preparing for the upcoming Phase 2 PAVIA trial results of EYP-1901 for NPDR in Q2 2024 and the initiation of the Phase 3 LUGANO trial in wet AMD in the second half of the year. The company's pipeline leverages its proprietary Durasert E™ technology for sustained intraocular drug delivery, with EYP-1901 being a leading product candidate. The announcement also included the grant of stock options to Dr. Ribeiro as an inducement award in accordance with Nasdaq Listing Rule 5635(c)(4).
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced on March 4, 2024, the appointment of Dr. Ramiro Ribeiro as its new Chief Medical Officer, effective March 1, 2024. Dr. Ribeiro, a trained retinal specialist, succeeds Dr. Dario Paggiarino, who has served in the role since 2016 and will depart the company on March 31, 2024. Dr. Ribeiro's previous experience includes serving as Vice President, Head of Clinical Development at Apellis Pharmaceuticals, where he led the global Phase 3 clinical program in Geographic Atrophy. EyePoint Pharmaceuticals is preparing for the upcoming Phase 2 PAVIA trial results of EYP-1901 for NPDR in Q2 2024 and the initiation of the Phase 3 LUGANO trial in wet AMD in the second half of the year. The company's pipeline leverages its proprietary Durasert E™ technology for sustained intraocular drug delivery, with EYP-1901 being a leading product candidate. The announcement also included the grant of stock options to Dr. Ribeiro as an inducement award in accordance with Nasdaq Listing Rule 5635(c)(4).
處於臨床階段的生物製藥公司EyePoint Pharmicals, Inc. 於2024年3月4日宣佈，任命拉米羅·裏貝羅博士爲新任首席醫學官，自2024年3月1日起生效。裏貝羅博士是一位訓練有素的視網膜專家，他接替了達里奧·帕賈裏諾博士。達里奧·帕賈裏諾博士自2016年以來一直擔任該職務，並將於2024年3月31日離開公司。裏貝羅博士之前的經歷包括在Apellis Pharmicals擔任副總裁兼臨床開發主管，在那裏他領導了《地理萎縮》的全球三期臨床項目。EyePoint Pharmaceuticals 正在爲即將於 2024 年第二季度發佈的 NPDR EYP-1901 第二階段 PAVI...展開全部
處於臨床階段的生物製藥公司EyePoint Pharmicals, Inc. 於2024年3月4日宣佈，任命拉米羅·裏貝羅博士爲新任首席醫學官，自2024年3月1日起生效。裏貝羅博士是一位訓練有素的視網膜專家，他接替了達里奧·帕賈裏諾博士。達里奧·帕賈裏諾博士自2016年以來一直擔任該職務，並將於2024年3月31日離開公司。裏貝羅博士之前的經歷包括在Apellis Pharmicals擔任副總裁兼臨床開發主管，在那裏他領導了《地理萎縮》的全球三期臨床項目。EyePoint Pharmaceuticals 正在爲即將於 2024 年第二季度發佈的 NPDR EYP-1901 第二階段 PAVIA 試驗結果以及下半年在溼性 AMD 中啓動的 3 期 LUGANO 試驗做準備。該公司的產品線利用其專有的 Durasert E™ 技術實現持續的眼內藥物輸送，其中 EYP-1901 是領先的候選產品。該公告還包括根據納斯達克上市規則5635（c）（4）向裏貝羅博士授予股票期權作爲激勵獎勵。
有用
沒用
